Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Peihua Lu, Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Meiwei Gong, Hui Wang, Jiaqi Chen, Hongxing Liu, Min Xiong, Ying Liu, Lin Wang

Blood blood.2024024861.

https://doi.org/10.1182/blood.2024024861

Published: 2024

Includes: Supplemental data

Journal Articles

Sgr-2921, a Potent CDC7 Inhibitor, Demonstrates Significant Anti-Leukemic Responses in Patient-Derived AML Models Representing Difficult-to-Treat Disease

Hooman Izadi, Hui Wang, Christian Atsriku, Zef Konst, Adam Levinson, Joseph Piccotti, Steven Pirie-Shepherd, Lin Tang, Dan Weiss, Karen Akinsanya, Hamish Wright, Kristian K Jensen

Blood (2023) 142 (Supplement 1): 2801.

https://doi.org/10.1182/blood-2023-181826

Published: 2023

Journal Articles

One High Efficient Detection Panel of Multiparamer Flow Cytometry for Non-Hematopoietic Tumors

Meiwei Gong, Hui Wang

Blood (2023) 142 (Supplement 1): 7166.

https://doi.org/10.1182/blood-2023-179873

Published: 2023

Journal Articles

Methotrexate in Combination with Orelabrutinib, Thiotepa, and Rituximab (R-MTO) Followed By Autologous Stem-Cell Transplant for Primary Central Nervous System Lymphoma Treatment

Lijie Xing, Haichen Wei, Dan Liu, Hui Wang, Ping Li, Linna Xie, Zengjun Li

Blood (2023) 142 (Supplement 1): 6228.

https://doi.org/10.1182/blood-2023-186219

Published: 2023

Journal Articles

Study on the Impact of G-CSF Mobilization on the Level of MDSCs in Donor Peripheral Blood and Its Correlation with Patient Prognosis

Man Chen, Rong Wang, Hui Wang

Blood (2023) 142 (Supplement 1): 7021.

https://doi.org/10.1182/blood-2023-180871

Published: 2023

Journal Articles

Relevant Studies on Cytokines Level and CAR-T Expansion Associated to CD7 CAR-T Therapy

Dongchu Wang, Hui Wang

Blood (2023) 142 (Supplement 1): 6857.

https://doi.org/10.1182/blood-2023-180843

Published: 2023

Journal Articles

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Richard R. Furman, William G. Wierda, Anna Schuh, Piers EM Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd

Blood (2022) 140 (Supplement 1): 9873–9875.

https://doi.org/10.1182/blood-2022-162394

Published: 2022

Journal Articles

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Blood (2022) 140 (Supplement 1): 11962–11963.

https://doi.org/10.1182/blood-2022-162507

Published: 2022

Journal Articles

Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice

Lara M Breyer, Hui Wang, Dongsheng Gu, Brian H Johnstone, Huihui Ma, Erik J Woods, Markus Y. Mapara

Blood (2022) 140 (Supplement 1): 7347–7348.

https://doi.org/10.1182/blood-2022-169787

Published: 2022

Journal Articles

Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Qiang He, Linna Xie, Rongrong Zhao, Ji Ma, Hui Wang, Jie Li, Chuanli Zhao, Y. Lynn Wang, Zengjun Li

Blood (2022) 140 (Supplement 1): 6614–6615.

https://doi.org/10.1182/blood-2022-168859

Published: 2022

Journal Articles

Short-Term Efficacy and Safety of Haplo Hematopoietic Stem Cell Transplantation for Refractory and/or Relapsed Leukemia

Wei Zhao, Min Xiong, Yanli Zhao, Man Chen, Hui Wang, Peihua Lu

Blood (2022) 140 (Supplement 1): 12961–12962.

https://doi.org/10.1182/blood-2022-166724

Published: 2022

Journal Articles

Developing CD70-Targeted CAR-T Cells for the Treatment of Hematological and Solid Malignancies

Yuan Lu, Hui Huang, Cheng Chen, Hui Wang, Huilin Wu, Xiaoqin Liu, Wei Zhao, Chunyan Gao, Siyuan Tan

Blood (2022) 140 (Supplement 1): 12695.

https://doi.org/10.1182/blood-2022-160106

Published: 2022

Journal Articles

Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions

Yi Wang, Hui Wang, Ben Niu, Ying Gao, Ding Zhang, Yudi Miao, Wei Zhou, Limin Hou, Hong Zhang, Xingxing Hu, Fangyuan Wang, Lan Li, Xingli Ru, Weihua Zhang, Xiang Li, Feng Guan

Blood (2022) 140 (Supplement 1): 10287.

https://doi.org/10.1182/blood-2022-168561

Published: 2022

Journal Articles

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Piers EM Patten, Talha Munir, Krish Patel, Anna Butturini, Marianne de Borja, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2022) 140 (Supplement 1): 9865–9867.

https://doi.org/10.1182/blood-2022-159542

Published: 2022

Journal Articles

SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up

Hui Wang, Ying Gao, Ding Zhang, Yan Zheng, Xingxing Hu, Qiuying Gao, Ben Niu, Limin Hou, Ling Wang, Weihua Zhang, Yi Zhang, Xingli Ru, Le Li, Zuohan Peng, Yi Wang

Blood (2022) 140 (Supplement 1): 4623–4624.

https://doi.org/10.1182/blood-2022-159871

Published: 2022

Journal Articles

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Peihua Lu, Ying Liu, Junfang Yang, Xian Zhang, Xiao Yang, Hui Wang, Lin Wang, Qinglong Wang, David Jin, Jianqiang Li, Xiaojun Huang

Blood (2022) 140 (4): 321–334.

https://doi.org/10.1182/blood.2021014498

Published: 2022

Includes: Supplemental data

Journal Articles

A Preliminary Study on the Safety and Efficacy of a Novel Human BCMA-Targeting CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Yi Wang, Ying Gao, Hui Wang, Ding Zhang, Yan Zheng, Xingxing Hu, Qiuying Gao, Ben Niu, Hong Zhang, Wei Zhou, Weihua Zhang, Xingli Ru, Fangyuan Wang

Blood (2021) 138 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2021-152651

Published: 2021

Journal Articles

Clinical Analysis of Air-Leak Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients

Wei Zhao, Man Chen, Yanli Zhao, Hui Wang, Peihua Lu, Min Xiong

Blood (2021) 138 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2021-152138

Published: 2021

Journal Articles

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Junfang Yang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 473.

https://doi.org/10.1182/blood-2021-147667

Published: 2021

Journal Articles

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Junfang Yang, Xiao Yang, Ying Liu, Qinglong Wang, Hui Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 652.

https://doi.org/10.1182/blood-2021-147754

Published: 2021

NARROW

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Sgr-2921, a Potent CDC7 Inhibitor, Demonstrates Significant Anti-Leukemic Responses in Patient-Derived AML Models Representing Difficult-to-Treat Disease

One High Efficient Detection Panel of Multiparamer Flow Cytometry for Non-Hematopoietic Tumors

Methotrexate in Combination with Orelabrutinib, Thiotepa, and Rituximab (R-MTO) Followed By Autologous Stem-Cell Transplant for Primary Central Nervous System Lymphoma Treatment

Study on the Impact of G-CSF Mobilization on the Level of MDSCs in Donor Peripheral Blood and Its Correlation with Patient Prognosis

Relevant Studies on Cytokines Level and CAR-T Expansion Associated to CD7 CAR-T Therapy

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial

Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice

Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Short-Term Efficacy and Safety of Haplo Hematopoietic Stem Cell Transplantation for Refractory and/or Relapsed Leukemia

Developing CD70-Targeted CAR-T Cells for the Treatment of Hematological and Solid Malignancies

Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

A Preliminary Study on the Safety and Efficacy of a Novel Human BCMA-Targeting CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Clinical Analysis of Air-Leak Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only